Selected article for: "complement activation and lung injury"

Author: Sun, Shihui; Jiang, Yuting; Wang, Renxi; Liu, Chenfeng; Liu, Xiaoling; Song, Nianping; Guo, Yan; Guo, Renfeng; Du, Lanying; Jiang, Shibo; Li, Yan; Qiu, Zewu; Zhao, Guangyu; Zhou, Yusen
Title: Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application*
  • Document date: 2018_4_13
  • ID: 6ztwho9k_33
    Snippet: Evidence indicates that therapeutic modulation of C5a or C5 is a promising treatment for inflammatory disorders (43) . Different from other complement blocking agents such as eculizumab, IFX-1 provides effective and specific blockade of C5a without disturbing the C5b assembly arm required for MAC formation (11) ; this may play an important role in host defense against secondary bacterial and fungal pneumonia that typically occurs in patients who .....
    Document: Evidence indicates that therapeutic modulation of C5a or C5 is a promising treatment for inflammatory disorders (43) . Different from other complement blocking agents such as eculizumab, IFX-1 provides effective and specific blockade of C5a without disturbing the C5b assembly arm required for MAC formation (11) ; this may play an important role in host defense against secondary bacterial and fungal pneumonia that typically occurs in patients who suffer from ALI. Previously, we showed that IFX-1 effectively inhibits eC5a in humans and African Green Monkeys, thereby alleviating lung injury induced by H7N9 virus (11) . Here, we found that C5a remained at basal levels after IFX-1 treatment, indicating that C5a can be effectively blocked without affecting the upstream pathways of complement activation.

    Search related documents:
    Co phrase search for related documents